CDK4/6 inhibitors enhance oxaliplatin efficacy in colorectal cancer with RB-dependent and tumor-selective activity in intestinal model
Alana S O Souza, Julia S. M. Conceição, Letícia Silva Ferraz, João Marcos de Azevedo Delou, Bruna Rodrigues Cardoso Miranda, Carla Verissimo, Mayra Carneiro, Stevens Kastrup Rehen, Martín Bonamino, Helena L. Borges
This study shows CDK4/6 inhibitors synergize with oxaliplatin in colorectal cancer, with RB-dependent tumor-selective activity and preserved efficacy at low inhibitor doses.
bioRxiv · Apr 19, 2026 · PreprintCancer Biology